SYRE
Spyre Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +20.8% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 99 | +22 | 55.43M | $4.93B | +25 | −3 |
| Q1 2026 | 80 | +10 | 41.69M | $2.10B | +12 | −2 |
| Q4 2025 | 69 | +2 | 41.90M | $1.37B | +2 | — |
| Q3 2025 | 13 | -1 | 23.21M | $388.94M | +1 | −2 |
| Q2 2025 | 11 | 0 | 22.40M | $335.38M | +2 | −2 |
| Q1 2025 | 8 | -2 | 6.01M | $96.96M | — | −2 |
| Q4 2024 | 10 | +1 | 7.67M | $178.64M | +2 | −1 |
| Q3 2024 | 8 | 0 | 4.78M | $140.58M | +1 | −1 |
| Q2 2024 | 8 | — | 3.96M | $93.00M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 1.51M | +89.4% | $44.33M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 1.51M | +89.4% | $44.33M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 1.51M | +89.4% | $44.33M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 1.51M | +89.4% | $44.33M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Adage Capital Partners ✦ | 1.05M | -8.4% | $31.03M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 891.05K | +16.4% | $26.21M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 891.05K | +16.4% | $26.21M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 707.59K | 0.0% | $20.81M | 0.0% | Held | 2 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 429.13K | +39.3% | $12.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 429.13K | +39.3% | $12.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Soros Fund Management ✦ | 145.00K | 0.0% | $4.26M | 0.1% | Held | 2 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 35.00K | New | $1.03M | 0.0% | New | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 35.00K | New | $1.03M | 0.0% | New | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 35.00K | New | $1.03M | 0.0% | New | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 9.80K | -0.4% | $288,306 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $1.03M | 0.0% |
| AQR Capital Management | $1.03M | 0.0% |
| AQR Capital Management | $1.03M | 0.0% |
Exited
| Norges Bank | $1.67M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 197 holders, 82.12M shares, $4.06B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 5.00K sh · $522,350
Director · 8.00K sh · $835,040
Director · 10.00K sh · $1.05M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
9.2% of class · View original SEC filing ↗